Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers

References

• Begley DJ. (2004). ABC transporters and the blood-brain barrier. Curr Pharm Des, 10, 1295–1312.
   PubMed Web of Science ®Google Scholar
• Brandes AA, Pasetto LM, Monfardini S. (2000). New drugs in recurrent high grade gliomas. Anticancer Res, 20, 1913–1920.
   PubMed Web of Science ®Google Scholar
• Breedveld P, Beijnen JH, Schellens JH. (2006). Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci, 27, 17–24.
   PubMed Web of Science ®Google Scholar
• Carroll RT, Bhatia D, Geldenhuys W, Bhatia R, Miladore N, Bishayee A, Sutariya V. (2010). Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target, 18, 665–674.
   PubMed Web of Science ®Google Scholar
• Das D, Lin S. (2005). Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci, 94, 1343–1353.
   PubMed Web of Science ®Google Scholar
• Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, Jiang SW. (2006). Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther, 5, 2767–2776.
   PubMed Web of Science ®Google Scholar
• Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, Egorin MJ. (1994). Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol, 34, 465–471.
   PubMed Web of Science ®Google Scholar
• Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G. (2002). Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest, 110, 1309–1318.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Visser CC, de Boer AG. (2005). Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv, 2, 299–309.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ. (2010). Glutathione-based drug delivery system. PCT Int. Appl. 52pp. CODEN: PIXXD2 WO 2010095940 A2 20100826.
   Google Scholar
• Gallo JM, Li S, Guo P, Reed K, Ma J. (2003). The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res, 63, 5114–5117.
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Chamberlain MC, Chang SM, Prados MD, Cole BF. (1999). The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol, 9, 27–33.
   PubMed Web of Science ®Google Scholar
• Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA, 105, 2586–2591.
   PubMed Web of Science ®Google Scholar
• Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, Beijnen JH. (1994). Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol, 5, 951–953.
   PubMed Web of Science ®Google Scholar
• Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, Jiang X. (2009). Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release, 134, 55–61.
   PubMed Web of Science ®Google Scholar
• Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O. (2004). Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev, 30, 415–423.
   PubMed Web of Science ®Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. (2004). Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release, 99, 259–269.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47, 65–81.
   PubMed Web of Science ®Google Scholar
• Li KW, Dang W, Tyler BM, Troiano G, Tihan T, Brem H, Walter KA. (2003). Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin Cancer Res, 9, 3441–3447.
   PubMed Web of Science ®Google Scholar
• Liang HF, Chen YC, Yang TF, Chang LW, Wang AJ, Lu JM, Jan CH, Lin YF, Liu S. (2008). Glutathione based delivery system for analgesics. U.S. Pat. Appl. Publ. 18pp., Cont.-in-part of U.S. Ser. No. 303,934.
   Google Scholar
• Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. (2003). Brain uptake of thiamine-coated nanoparticles. J Control Release, 93, 271–282.
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. (2003). A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release, 86, 33–48.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. (2007). Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release, 124, 163–171.
   PubMed Web of Science ®Google Scholar
• Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. (1999). Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res, 16, 1836–1842.
   PubMed Web of Science ®Google Scholar
• Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. (2002). Synthesis of pegylated immunonanoparticles. Pharm Res, 19, 1137–1143.
   PubMed Web of Science ®Google Scholar
• Olivier JC. (2005). Drug transport to brain with targeted nanoparticles. NeuroRx, 2, 108–119.
   PubMedGoogle Scholar
• Pardridge WM. (2004). Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther, 4, 1103–1113.
   PubMed Web of Science ®Google Scholar
• Ren T, Xu N, Cao C, Yuan W, Yu X, Chen J, Ren J. (2009). Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles. J Biomater Sci Polym Ed, 20, 1369–1380.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Labhasetwar V. (2005). Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm, 2, 373–383.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. (1996). Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs, 7, 78–86.
   PubMed Web of Science ®Google Scholar
• Sun W, Xie C, Wang H, Hu Y. (2004). Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials, 25, 3065–3071.
   PubMed Web of Science ®Google Scholar
• Tanner PG, Holtmannspötter M, Tonn JC, Goldbrunner R. (2007). Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery, 61, E880–2; discussion E882.
   PubMed Web of Science ®Google Scholar
• Wang AJ, Jian CH, Li SD, Lin YF, Liu S. (2007). Glutathione based delivery system. U.S. Pat. Appl. Publ. 13pp. CODEN: USXXCO US 2007141133 A1 20070621 CAN 147:102147 AN 2007:672399.
   Google Scholar
• Xie J, Lei C, Hu Y, Gay GK, Bin Jamali NH, Wang CH. (2010). Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer. Curr Pharm Des, 16, 2331–2340.
   PubMed Web of Science ®Google Scholar